CARMEL, Ind., April 1, 2024 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS) is developing neuromodulatory therapies to address chronic and debilitating diseases. A commercializing medical technology company. The children and adults company plans to report its financial results for the fourth quarter and fiscal year of 2023 for the period ending December 31, 2023 on Tuesday, April 9, 2024, after the market closes. The Company has scheduled a conference call for the same day, Tuesday, April 9, 2024, at 4:30 p.m. Eastern Time, to discuss the results.
Conference call details
Date and time: Tuesday, April 9, 2024, 4:30 PM ET
Live webcast information: Interested parties can access the conference call via live webcast. A live webcast will be available on the Investor Relations section of our website at https://edge.media-server.com/mmc/p/mir4a7uc or https://ir.neuraxis. .com/. Participants listening through the webcast can submit questions by using the “Ask a Question” link on the portal or by emailing NRXS@lythampartners.com.
Call-in information: Interested parties can also access the live conference call by first registering at the link below. Once the registration link is completed, the call-in participant will receive a confirmation email with dial-in information and her unique PIN to join the call, as well as details.
replay: A replay of the webcast is available on the Investor Relations section of our website at https://edge.media-server.com/mmc/p/mir4a7uc or https://ir.neuraxis.com/ .
10-K filing
Today, the Company filed a Form NT 10-K with the SEC, providing notice of its inability to file a Form 10-K on the prescribed deadline. Form NT is exempt from filing later than 15 calendar days after the stated deadline. As set forth in this press release, the Company plans to file its Form 10-K on April 9, 2024. The Company is unable to file in a timely manner primarily due to special circumstances related to the Company’s IPO last year.
About NeurAxis Co., Ltd.
NeurAxis, Inc. is a medical technology company focused on neuromodulatory therapies that address chronic debilitating conditions in children and adults. NeurAxis is committed to the advancement of science and the use of evidence-based medicine and encourages the adoption of his IB-Stim™ therapy, a proprietary transcutaneous electrical nerve field stimulation (PENFS) technology, by the medical, scientific, and patient communities. We are promoting it. IB-Stim™ is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents ages 11-18. Additional clinical trials of PENFS are underway in multiple pediatric and adult diseases with significant unmet medical needs. For more information, please visit http://neuraxis.com.
Forward-looking statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations about future events and trends that will or may impact our business, strategy, operations or financial performance; Actual results and other events may differ materially from those expressed or implied by the forward-looking statements. We do not make such statements because there are a number of risks and uncertainties. Forward-looking statements inherently involve risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated in the forward-looking statements in this press release. These factors include, among other things, U.S. and global economic conditions, the trading price and volatility of our stock, public health issues or other events, our compliance with applicable laws, and the results and perceptions of our clinical trials. its contents, the results of its filings with the FDA, the results of the shareholder vote enabling the issuance of the preferred stock, and the factors described in the Risk Factors section of NeurAxis’ public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements inherently involve risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company does not intend to make any changes, whether as a result of new information, future events and otherwise. We undertake no obligation to update or revise these statements. development and other things.
contact address:
company
New Axis Co., Ltd.
info@neuraxis.com
PR for investors
Ben Shamsyan
Lytham Partners
646-829-9701
shamsian@lythampartners.com
